Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 15, 2021

SELL
$18.39 - $24.8 $166,760 - $224,886
-9,068 Closed
0 $0
Q3 2020

Oct 15, 2020

SELL
$20.67 - $26.94 $96,156 - $125,324
-4,652 Reduced 33.91%
9,068 $222,000
Q1 2020

Apr 16, 2020

BUY
$14.46 - $21.8 $198,391 - $299,096
13,720 New
13,720 $236,000
Q4 2019

Jan 17, 2020

SELL
$15.15 - $18.89 $221,886 - $276,662
-14,646 Closed
0 $0
Q3 2019

Oct 09, 2019

SELL
$17.68 - $22.65 $477 - $611
-27 Reduced 0.18%
14,646 $259,000
Q2 2019

Jul 23, 2019

BUY
$18.93 - $24.75 $277,759 - $363,156
14,673 New
14,673 $314,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Arden Trust CO Portfolio

Follow Arden Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arden Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Arden Trust CO with notifications on news.